Measuring the symptom burden associated with the treatment of chronic myeloid leukemia

Blood

Volumn 122, Issue 5, 2013, Pages 641-647

  Williams, Loretta A ^a   Gonzalez, Araceli G Garcia ^a   Ault, Patricia ^a   Mendoza, Tito R ^a   Sailors, Mary L ^a   Williams, Janet L ^a   Huang, Furong ^a   Nazha, Aziz ^a   Kantarjian, Hagop M ^a   Cleeland, Charles S ^a   Cortes, Jorge E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BAFETINIB; BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; REBASTINIB;

ADULT; ARTICLE; CAREGIVER; CAREGIVER BURDEN; CHRONIC MYELOID LEUKEMIA; COMORBIDITY; CONSTRUCT VALIDITY; CONTENT ANALYSIS; CONTROLLED STUDY; DIARRHEA; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; DROWSINESS; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEMATOPOIETIC STEM CELL; HUMAN; INTERNAL CONSISTENCY; MAJOR CLINICAL STUDY; MALE; MD ANDERSON SYMPTOM INVENTORY; MUSCLE CRAMP; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; NAUSEA; PARESTHESIA; PRIORITY JOURNAL; QUALITATIVE ANALYSIS; SLEEP DISORDER; SWELLING; SYMPTOM; SYMPTOM ASSESSMENT; TEST RETEST RELIABILITY; VOMITING; XEROSTOMIA; AGED; CLINICAL TRIAL; COGNITION; COHORT ANALYSIS; COST OF ILLNESS; INTERVIEW; LONGITUDINAL STUDY; METHODOLOGY; MIDDLE AGED; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; QUESTIONNAIRE; REPRODUCIBILITY;

ADULT; AGED; COGNITION; COHORT STUDIES; COST OF ILLNESS; FEMALE; HUMANS; INTERVIEWS AS TOPIC; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN;

EID: 84886394855     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-01-477687     Document Type: Article

References (36)

1. Huang X, Cortes J, Kantarjian H. Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy. Cancer. 2012; 118(12): 3123-3127.
2. Efficace F, Baccarani M, Breccia M., et al.; GIMEMA. Health-related quality of life in chronic myeloid leukemia patients receiving long-term therapy with imatinib compared with the general population. Blood. 2011; 118(17): 4554-4560.
3. Marin D, Bazeos A, Mahon F.X., et al. Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib. J Clin Oncol. 2010; 28(14): 2381-2388.
4. Pinilla-Ibarz J., Cortes J, Mauro MJ. Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: Definitions and clinical implications. Cancer. 2011; 117(4): 688-697.
5. Postel-Vinay S., Gomez-Roca C, Molife L.R., et al. Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities? J Clin Oncol. 2011; 29(13): 1728-1735.
6. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol. 1997; 96(1): 111-116.
7. Basch E, Jia X, Heller G., et al. Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009; 101(23): 1624-1632.
8. Kiss TL, Abdolell M, Jamal N., Minden MD, Lipton JH, Messner HA. Long-term medical outcomes and quality-of-life assessment of patients with chronic myeloid leukemia followed at least 10 years after allogeneic bone marrow transplantation. J Clin Oncol. 2002; 20(9): 2334-2343. (Pubitemid 34441661)
9. Aziz Z, Iqbal J, Aaqib M., Akram M, Saeed A. Assessment of quality of life with imatinib mesylate as first-line treatment in chronic phase-chronic myeloid leukemia. Leuk Lymphoma. 2011; 52(6): 1017-1023.
10. Hahn EA, Glendenning GA, Sorensen M.V., et al.; IRIS Investigators. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study. J Clin Oncol. 2003; 21(11): 2138-2146. (Pubitemid 46606362)
11. Trask PC, Cella D, Besson N., Kelly V, Masszi T, Kim DW. Health-related quality of life of bosutinib (SKI-606) in imatinib-resistant or imatinib-intolerant chronic phase chronic myeloid leukemia. Leuk Res. 2012; 36(4): 438-442.
12. Trask PC, Cella D, Powell C., Reisman A, Whiteley J, Kelly V. Health-related quality of life in chronic myeloid leukemia. Leuk Res. 2013; 37(1): 9-13.
13. Efficace F, Cartoni C, Niscola P., et al. Predicting survival in advanced hematologic malignancies: do patient-reported symptoms matter? Eur J Haematol. 2012; 89(5): 410-416.
14. Cleeland CS, Mendoza TR, Wang X.S., et al. Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer. 2000; 89(7): 1634-1646.
15. Basch E, Abernethy AP, Mullins C.D., et al. Recommendations for incorporating patient-reported outcomes into clinical comparative effectiveness research in adult oncology. J Clin Oncol. 2012; 30(34): 4249-4255.
16. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: a systematic review. J Clin Oncol. 2006; 24(9): 1459-1473. (Pubitemid 46622014)
17. Armstrong TS, Mendoza T, Gning I., et al. Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol. 2006; 80(1): 27-35. (Pubitemid 44473259)
18. published correction appears in J Neurooncol. 2006; 80(1): 37
19. Gning I, Trask PC, Mendoza T.R., et al. Development and initial validation of the thyroid cancer module of the M. D. Anderson Symptom Inventory. Oncology. 2009; 76(1): 59-68.
20. Rosenthal DI, Mendoza TR, Chambers M.S., et al. Measuring head and neck cancer symptom burden: the development and validation of the M. D. Anderson symptom inventory, head and neck module. Head Neck. 2007; 29(10): 923-931.
21. Wang XS, Williams LA, Eng C, et al. Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). Cancer. 2010; 116(8): 2053-2063.
22. Mendoza TR, Wang XS, Lu C, et al. Measuring the symptom burden of lung cancer: the validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist. 2011; 16(2): 217-227.
23. Fadol A, Mendoza T, Gning I., et al. Psychometric testing of the MDASI-HF: a symptom assessment instrument for patients with cancer and concurrent heart failure. J Card Fail. 2008; 14(6): 497-507.
24. Williams LA, Couriel DR, Mendoza T.R., et al. A new measure of symptom burden in chronic graftversus-host disease [abstract]. Biol Blood Marrow Transplant. 2010; 16(2 suppl 2):S177. Abstract 60.
25. Nikitina T, Fedorenko DA, Kurbatova K.A., et al. The new instrument for comprehensive symptom assessment in patients with chronic myeloid leukemia [abstract]. Qual Life Res. 2012; 21(suppl 1): 69. Abstract 1080.
26. Efficace F, Breccia M, Saussele S., et al. International Development of An EORTC measure to assess Patient-reported quality of life (QoL) and symptoms in chronic myeloid leukemia (CML) [abstract]. Blood. 2011; 118(21). Abstract 3132.
27. Stalfelt AM, Zettervall O. Quality of life in young patients with chronic myelocytic leukaemia during intensive treatment including interferon. Leuk Res. 1997; 21(8): 775-783. (Pubitemid 27458630)
28. US Food and Drug Administration. Guidance for industry. Patient-reported outcome measures: use in medical product development to support labeling claims. FDA website. http://www.fda.gov/downloads/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/UCM071975.pdf. Accessed January 6, 2013.
29. Sloan JA, Loprinzi CL, Kuross S.A., et al. Randomized comparison of four tools measuring overall quality of life in patients with advanced cancer. J Clin Oncol. 1998; 16(11): 3662-3673. (Pubitemid 28506782)
30. Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis. 1981; 34(12): 585-597. (Pubitemid 12237535)
31. Parse RR, Coyne AB, Smith MJ. Nursing Research: Qualitative Methods. Bowie, MD: Brady Communications; 1985.
32. Nunnally JC, Bernstein IH. Psychometric Theory. New York, NY: McGraw-Hill; 1994.
33. Cohen J. Statistical Power Analysis for the Behavioral Sciences, 2nd ed. Hillsdale, NJ: Lawrence Earlbaum Associates; 1988.
34. Cohen J. A power primer. Psychol Bull. 1992; 112(1): 155-159.
35. Harman HH. Modern Factor Analysis. Chicago, IL: University of Chicago Press; 1967.
36. Sloan JA, Vargas-Chanes D, Kamath C.C., Sargent DJ, Novotny PJ, Atherton P. Detecting worms, ducks and elephants: a simple approach for defining clinically relevant effects in qualty-of-life measures. J Cancer Integr Med. 2003; 1(1): 41-47.